<a href="https://www.fiercebiotech.com/biotech/calls-coins-act-expansion-grow-new-rules-sweep-china-biotech-licensing" hreflang="en">As calls for COINS Act expansion grow, will new rules sweep up China biotech licensing?</a>
Calls are growing in the U.S. to expand the COINS Act to include biotechnology, aiming to restrict American investments in Chinese biotech as lawmakers express concerns over national security and long-term competitiveness. The proposed changes could complicate or inhibit U.S. pharmaceutical companies' ability to license Chinese biotech assets, prompting debate over the balance between safeguarding American innovation and ensuring access to new therapies.
The proposed expansion of the COINS Act to include biotech could significantly impact U.S.-China licensing deals, potentially slowing down dealmaking and raising costs for U.S. companies. This legislative change could force American pharma firms to refocus on domestic innovation, which may present new opportunities for investment in U.S. biotech startups. Monitoring the Treasury Department’s upcoming regulations is crucial, as they could redefine the landscape of international biotech collaboration and investment.